These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25212703)

  • 1. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
    Othman AA; Tran JQ; Tang MT; Dutta S
    Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
    Minocha M; Tran JQ; Sheridan JP; Othman AA
    Clin Pharmacokinet; 2016 Jan; 55(1):121-30. PubMed ID: 26242380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
    Tran JQ; Othman AA; Mikulskis A; Wolstencroft P; Elkins J
    Clin Pharmacol; 2016; 8():9-13. PubMed ID: 26929672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population PK-PD analyses of CD25 occupancy, CD56
    Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
    Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclizumab and its use in multiple sclerosis treatment.
    Milo R; Osherov M
    Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Patti F; Chisari CG; D'Amico E; Zappia M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):341-352. PubMed ID: 29363337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
    Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
    Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J
    J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
    Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
    Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
    Li J; Li X; Tan M; Lin B; Hou S; Qian W; Li B; Zhang D; Zhou B; Wang H; Zhu T; Guo Y
    MAbs; 2009; 1(1):49-55. PubMed ID: 20046574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
    Shida Y; Takahashi N; Sakamoto T; Ino H; Endo A; Hirama T
    J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
    Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
    AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
    Kielbasa W; Quinlan T
    J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.